Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Total Equity history
Currency unavailable · from the balance sheet
No Total Equity data reported for this period type.
Total Equity vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. | Sep 2026 | $1.2B USD | +145.9% | +124.6% | 97.2% |
| Sep 2026 | $1.05B USD | +131.1% | +142.3% | 95.6% | |
| Jun 2026 | $841.54M USD | +26.0% | +41.8% | 95.0% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $452.16M USD | -6.8% | — | 80.7% |
| Mar 2026 | $151.23M USD | +2960.5% | — | 79.7% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €146.93M EUR | — | — | 88.7% |
| Mar 2026 | $143.65M USD | -0.3% | -19.5% | 72.3% | |
| Mar 2026 | $12.75M USD | -62.5% | -47.8% | 3.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +26.0% | +41.8% | 84.7% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.